CEO/Founder Martine Rothblatt Files Intent to Sell $113M in Stock, Continuing Large Distribution Pattern
UTHR has more than doubled off its 52-week low of $272.12.
Summary
United Therapeutics' CEO and Founder, Martine Rothblatt, has filed a Form 144 indicating an intent to sell 209,000 shares of common stock, valued at approximately $113.2 million, extending a significant pattern of insider selling.
Key Events · Ownership and Investor Activity · UTHR
-
Proposed Insider Sale
Martine Rothblatt, CEO and Founder, has filed an intent to sell 209,000 shares of common stock.
-
Significant Transaction Value
The proposed sale is valued at approximately $113.2 million.
-
Ongoing Selling Pattern
This filing continues a trend of substantial insider selling by Rothblatt, who has already sold 579,500 shares for $326.3 million in the past three months under a 10b5-1 plan.
Analysis · UTHR · Life Sciences
This Form 144 filing reveals a significant intent to sell shares by Martine Rothblatt, the company's CEO and Founder. The proposed $113.2 million sale is substantial and adds to a consistent pattern of large insider distributions, with over $326 million in sales by Rothblatt in the last three months alone. Such sustained selling by a key executive can be interpreted as a lack of conviction in the company's near-term stock performance, despite the sales being part of a pre-planned 10b5-1 program.
At the time of this filing, UTHR was trading at $547.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.2B. The 52-week trading range was $272.12 to $609.35. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.